Navigation Links
A longer lasting tumor blocker
Date:4/28/2009

On the heels of dismaying reports that a promising antitumor drug could, in theory, shorten patients' long-term survival, comes a promising study by a Japanese team of researchers that suggests a potentially better option. The study appears in the May 11 issue of the Journal of Experimental Medicine (online April 27).

Many cancer treatments work by disrupting the formation of new blood vessels that feed growing tumors. Agents that block a vessel-promoting factor called VEGF have shown promise in human clinical trials. But recent studies in mice show that when treatment stops, tumor growth rapidly resumes. Now, Yoshiaki Kubota and colleagues find that blocking a different molecule, called M-CSF, suppressed tumor growth even after treatment was stopped.

Kubota and his team compared the efficacy of inhibitors against M-CSF and VEGF in mice with a certain kind of bone tumor. Three weeks of anti-VEGF treatment suppressed tumor growth but, similar to other recent reports, the tumors bounced back when the drug treatment was curtailed. Tumor growth in mice on a similar regiment of an M-CSF inhibitor remained suppressed in the absence of drug.

Another distinction between the two inhibitors was the type of vessel growth that was blocked. Blocking VEGF prevented dangerous vessels from growing such as those that feed tumors. But it also stopped beneficial vessels from growing, such as those that help injured tissues heal. Blocking M-CSF, on the other hand, only impeded bad vessel growth.

Most likely, the antiM-CSF treatment had a lasting effect because it resulted in damage to the scaffolding that surrounds cancerous vessels, robbing the tumors of the structural support they need to grow. Meanwhile, the scaffold of mice treated with anti-VEGF remained intact.

M-CSF levels soar in patients with osteosarcoma (a malignant bone cancer), breast cancer and prostate cancer, making these cancers potentially the most responsive to M-CSF-blocking drugs Whether or not other types of cancer rely more on M-CSF than on VEGF for their blood supply remains unknown.


'/>"/>

Contact: Amy Maxmen
amaxmen@rockefeller.edu
Rockefeller University Press
Source:Eurekalert

Related biology news :

1. Turtles no longer turned into souvenirs
2. Inactivity of proteins behind longer shelf life when freezing
3. No longer a gray area: Our hair bleaches itself as we grow older
4. Shorter wait means longer life for kidney transplant candidates
5. Living longer thanks to the longevity gene
6. For fats, longer may not be better
7. Deprived of a sense of smell, worms live longer
8. Formula discovered for longer plant life
9. The mystery of mass extinctions is no longer murky
10. Mouse study: When it comes to living longer, its better to go hungry than go running
11. Antioxidant users dont live longer, analysis of studies concludes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... PALM BEACH GARDENS, Fla. , April 11, ... biometric identity management and secure authentication solutions, today ... million contract by Intelligence Advanced Research Projects Activity ... technologies for IARPA,s Thor program. "Innovation ... the onset and IARPA,s Thor program will allow ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
Breaking Biology News(10 mins):
(Date:9/14/2017)... ... September 14, 2017 , ... Cambridge Semantics ... today announced that its Anzo Smart Data Lake has been named a ... and solutions that help organizations succeed in surpassing their knowledge management goals. KMWorld ...
(Date:9/12/2017)... ... September 12, 2017 , ... ... of their latest product LabCODE™, a novel Lab Information Management System (LIMS) ... capabilities for Biobanking, Pharmacokinetics, Pharmacogenetics, Next Generation Sequencing, Flow Cytometry, Pathology, and ...
(Date:9/12/2017)... Wayne, PA (PRWEB) , ... September 12, 2017 , ... ... and growing life sciences teams, today announced that Tobias Massa, PhD has joined the ... pharmaceuticals, biotech, life sciences, and technology to his Board position. Most recently he served ...
(Date:9/12/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... company, continues to strengthen its position as the clinical technology provider for small ... unified clinical trial suite. , Sponsors unfamiliar with DrugDev Spark can experience solutions ...
Breaking Biology Technology: